What is Acrivon Therapeutics, Inc.'s (ACRV) StockRank?

MoatMap's StockRank for Acrivon Therapeutics, Inc. (ACRV) is 27/100, with a Sell signal. This is a composite score combining Quality (28), Value (34), and Momentum (54) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Acrivon Therapeutics, Inc. have an economic moat?

Acrivon Therapeutics, Inc. (ACRV) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Acrivon Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Acrivon Therapeutics, Inc. (ACRV) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Acrivon Therapeutics, Inc. in?

Acrivon Therapeutics, Inc. (ACRV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ACRV

SellHot Air

Acrivon Therapeutics, Inc. · Healthcare · United States · $88M · Avg Vol: $695K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-64.6%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Acrivon Predictive Precision Medicine (APPM) platform to develop targeted oncology therapeutics. The platform enables the identification of patient-specific protein biomarkers to predict drug response, matching the right patient with the right therapy. Acrivon's competitive moat is defined by this precision medicine approach, which aims to significantly increase clinical trial success rates for its pipeline candidates.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	0	0	0	0	—	—	—	0.1M	—
EPS	-7.56	-2.74	-2.38	-2.02	—	-1.88	-1.89	-1.69	—
Shares	21.9M	22.5M	31.2M	31.6M	+44.4%	—	—	—	—
Debt	5.0M	4.6M	3.6M	2.7M	-18.3%	2.1M	—	—	—
Equity	170.5M	121.2M	176.8M	112.5M	-12.9%	—	—	—	—
Op CF	-30.1M	-42.6M	-65.7M	-63.7M	—	-62.9M	—	—	—
Inv CF	-141.7M	50.7M	-51.8M	66.1M	—	—	—	—	—
Fin CF	101.7M	-1.6M	121.0M	-0.7M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+39.2%

SMA 50SMA 200

$1.99

RSI (14)

28.3

52W High

$3.56

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-73.7%10.0

ROE

-64.6%15.1

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-31.5%12.7

Piotroski

29.5

Int. Cover

—N/A

D/E Ratio

0.02x78.1

Current Ratio

7.99x83.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-0.0x25.0

P/FCF

—N/A

P/B

1.1x84.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

56%29.9

RS 6M

7%72.1

SMA 50/200

1.01x59.7

EPS Rev 4W

+13.6%91.9

EPS Rev 12W

+13.6%88.2

EPS Improve

+10%27.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$88M

P/E (Forward)

-1.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACRV are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ACRV	Acrivon Therapeutics, Inc.(you)	$88M	27	Sell
PTHS	Pelthos Therapeutics Inc.	$95M	25	Sell
SEER	Seer, Inc.	$110M	28	Sell
APLM	Apollomics, Inc.	$77M	29	Sell
XBIT	XBiotech Inc.	$69M	27	Sell
ATRA	Atara Biotherapeutics, Inc.	$92M	23	Sell
ACET	Adicet Bio, Inc.	$85M	22	Sell
RNXT	RenovoRx, Inc.	$75M	31	Sell
CSBR	Champions Oncology, Inc.	$68M	29	Sell
MNOV	MediciNova, Inc.	$71M	24	Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%

Acrivon Therapeutics, Inc. (ACRV): Stock Score Summary

Acrivon Therapeutics, Inc. (ACRV) has a MoatMap StockRank of 27/100 based on Quality (28/100), Value (34/100), and Momentum (54/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$1.99
Market Cap	$88M
P/E (Forward)	-1.26
Price/Book	1.05
Return on Equity	-64.6%
Return on Invested Capital	-73.7%
Debt/Equity	0.02x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-41M

Acrivon Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Acrivon Therapeutics, Inc.’s (ACRV) StockRank?: MoatMap’s StockRank for Acrivon Therapeutics, Inc. (ACRV) is 27/100, with a Sell signal. It is a composite of Quality (28), Value (34), and Momentum (54) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Acrivon Therapeutics, Inc. have an economic moat?: Acrivon Therapeutics, Inc. (ACRV) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Acrivon Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Acrivon Therapeutics, Inc. (ACRV) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Acrivon Therapeutics, Inc. in?: Acrivon Therapeutics, Inc. (ACRV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).